Novexel – Acquired by AstraZeneca in 2010 for more than $500 million. Novexel is an emerging specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever-increasing resistance to marketed antibiotics has led to a clear need for novel anti-infective agents that are active against multi-drug resistant bacteria.